Back to results
US 10,912,827 B2Granted
Means and methods for treating HBV
AssigneeHelmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsUlrike Protzer, Tanja Bauer, Anna Kosinska, Martin Mueck-Haeusl
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.
Claims21
A recombinant vaccination vector expressing
- (a) an envelope protein (HBs-antigen) from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and
- (b) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw;
- and at least one of the following:
- (c) an immunogenic envelope protein (HBs-antigen) from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 1;
- and/or
- (d) an immunogenic core protein (HBc-antigen) from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 2;
- and/or
- (e) an immunogenic RT domain of a polymerase from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 3.
9 more elements
A vaccination method against hepatitis B, wherein the method comprises:
- (i) administering to a subject
- (a′) an envelope protein from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and/or
- (b′) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw;
- and
- (ii) administering to the subject a MVA virus expressing
- (a) an envelope protein (HBs-antigen) from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and a MVA virus expressing
- (b) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw.
6 more elements
A vaccination method against hepatitis B, wherein the method comprises:
- (i) administering a subject
- (a′) an envelope protein from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and/or
- (b′) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw;
- and
- (ii) administering to the subject a MVA virus expressing
- (a) an envelope protein (HBs-antigen) from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and
- (b) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw.
6 more elements
An expression cassette comprising nucleic acids encoding:
- (a) an envelope protein (HBs-antigen) from hepatitis B virus serotype adw, wherein the envelope protein is preferably a small or large envelope protein from hepatitis B virus genotype A serotype adw, wherein the small or large envelope protein is preferably a small envelope protein;
- and
- (b) a core protein (HBc-antigen) from hepatitis B virus serotype ayw, wherein the core protein is preferably from hepatitis B virus genotype D serotype ayw;
- and at least one of the following:
- (c) an immunogenic envelope protein (HBs-antigen) from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 1;
- and/or
- (d) an immunogenic core protein (HBc-antigen) from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 2;
- and/or
- (e) an immunogenic RT domain of a polymerase from hepatitis B virus having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 3.
9 more elements
Dependencies are inferred from the claim text.